Castration-Resistant Prostate Carcinoma

Castration-Resistant Prostate Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

553 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 221
Recruiting: 123
Ph III recruiting: 12
Growth YoY: +25%
Industry share: 45%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (94)

clinicaltrialsPublishedShowing 51–100 of 553 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05171816	Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)	active not recruiting	Phase 3	110	AstraZenecaINDUSTRY	1	Aug 28, 2026	clinicaltrials
NCT07218666	Zanzalintinib in Men With Aggressive Variant Prostate Cancer(NAPOLEON)	recruiting	Phase 2	30	Deepak KilariOTHER	1	Aug 28, 2026	clinicaltrials